[Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases].
Okawa
Yutaka
Y
Aiba
Keisuke
K
D015703:Antigens, CD / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D001323:Autoantibodies / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D061988:Proteasome Inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D063268:Sialic Acid Binding Ig-like Lectin 3; D013792:Thalidomide / Q000627:therapeutic use*; D014801:Vitamin A / Q000627:therapeutic use*
D015703:Antigens, CD; D018951:Antigens, CD20; D015214:Antigens, Differentiation, Myelomonocytic; D001323:Autoantibodies; C571163:CD33 protein, human; D061988:Proteasome Inhibitors; D063268:Sialic Acid Binding Ig-like Lectin 3; D014801:Vitamin A; D013792:Thalidomide; D011505:Protein-Tyrosine Kinases